IPSIndian Journal of Pharmacology
Home  IPS  Feedback Subscribe Top cited articles Login 
Users Online : 1996 
Small font sizeDefault font sizeIncrease font size
Navigate Here
 »   Next article
 »   Previous article
 »   Table of Contents

Resource Links
 »   Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
 »   Citation Manager
 »   Access Statistics
 »   Reader Comments
 »   Email Alert *
 »   Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1597    
    Printed103    
    Emailed2    
    PDF Downloaded198    
    Comments [Add]    

Recommend this journal

 

 REVIEW ARTICLE
Year : 1997  |  Volume : 29  |  Issue : 5  |  Page : 281-288

Endothelins: A brief review



Correspondence Address:
S Balakrishnan


Login to access the Email id

Source of Support: None, Conflict of Interest: None


Rights and PermissionsRights and Permissions

The endothelin family of peptides are very potent endogenous vasoconstrictor and pressor agents, secreted by various cells and tissues in the human body. Of the 3 isoforms, endothelin is the major isoform produced by the vascular endothelium. Two endothelin receptor subtypes have so far been cloned in mammalian species, ETA and ETB. Since their discovery in 1988, the endothelins have been the subject of intense research on their physiological function and potential pathophysiological role in various disease states. There is now good evidence that endothelin regulates vascular tone and blood pressure and is important in the regulation of various functions like pulmonary, endocrine, central nervous system and foetal development. Studies with endothelin receptor antagonists have underlined the important role of endothelins in various disease states like chronic heart failure, hypertension, bronchial asthma, subarachinoid haemorrhage, vasospastic disorders and some developmental disorders. There are now a number of selective ETA and combined ETA/B receptor antagonists available for preclinical studies. Some of these agents are currently being assessed in early phase clinical trials. However, it is still not clear which of these will prove to be of most therapeutic value.






[PDF]*


        
Print this article     Email this article

Site Map | Home | Contact Us | Feedback | Copyright and Disclaimer
Online since 20th July '04
Published by Wolters Kluwer - Medknow